Taysha Gene Therapies Inc. (TSHA): Price and Financial Metrics
TSHA Price/Volume Stats
| Current price | $2.88 | 52-week high | $3.89 |
| Prev. close | $3.06 | 52-week low | $0.50 |
| Day low | $2.85 | Volume | 281,078 |
| Day high | $3.07 | Avg. volume | 2,000,300 |
| 50-day MA | $1.90 | Dividend yield | N/A |
| 200-day MA | $1.32 | Market Cap | 185.66M |
TSHA Stock Price Chart Interactive Chart >
TSHA POWR Grades
- Growth is the dimension where TSHA ranks best; there it ranks ahead of 91.16% of US stocks.
- TSHA's strongest trending metric is Sentiment; it's been moving up over the last 179 days.
- TSHA ranks lowest in Quality; there it ranks in the 5th percentile.
TSHA Stock Summary
- Equity multiplier, or assets relative to shareholders' equity, comes in at -10.53 for TAYSHA GENE THERAPIES INC; that's greater than it is for just 2.22% of US stocks.
- As for revenue growth, note that TSHA's revenue has grown 283.81% over the past 12 months; that beats the revenue growth of 97.66% of US companies in our set.
- In terms of volatility of its share price, TSHA is more volatile than 95.68% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to TAYSHA GENE THERAPIES INC, a group of peers worth examining would be PTCT, STX, ABSI, PZG, and MIMO.
- TSHA's SEC filings can be seen here. And to visit TAYSHA GENE THERAPIES INC's official web site, go to www.tayshagtx.com.
TSHA Valuation Summary
- In comparison to the median Healthcare stock, TSHA's price/earnings ratio is 105.87% lower, now standing at -1.6.
- Over the past 36 months, TSHA's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for TSHA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| TSHA | 2023-09-18 | 20.8 | -5.4 | -1.6 | -1.8 |
| TSHA | 2023-09-15 | 22.1 | -5.7 | -1.7 | -1.9 |
| TSHA | 2023-09-14 | 22.7 | -5.9 | -1.8 | -1.9 |
| TSHA | 2023-09-13 | 20.5 | -5.3 | -1.6 | -1.7 |
| TSHA | 2023-09-12 | 20.3 | -5.2 | -1.6 | -1.7 |
| TSHA | 2023-09-11 | 23.5 | -6.1 | -1.8 | -2.0 |
TSHA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- TSHA has a Quality Grade of D, ranking ahead of 19.38% of graded US stocks.
- TSHA's asset turnover comes in at 0 -- ranking 441st of 682 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows TSHA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0 | NA | -535.259 |
| 2020-12-31 | 0 | NA | -329.577 |
TSHA Price Target
For more insight on analysts targets of TSHA, see our TSHA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $44.27 | Average Broker Recommendation | 1.29 (Strong Buy) |
Taysha Gene Therapies Inc. (TSHA) Company Bio
Taysha Gene Therapies, Inc. engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II on September 20, 2019 and is headquartered in Dallas, TX.
Latest TSHA News From Around the Web
Below are the latest news stories about TAYSHA GENE THERAPIES INC that investors may wish to consider to help them evaluate TSHA as an investment opportunity.
Taysha Gene Therapies Provides Update on TSHA-120 Program in Giant Axonal Neuropathy (GAN)Following Type C meeting feedback from the U.S. FDA, Taysha is discontinuing development of TSHA-120 in GAN due to challenges with study design feasibility for potential Biologics License Application (BLA) submission Taysha will pursue external strategic options for the TSHA-120 program to potentially enable further program development Strategic program prioritization will reduce operating expenses and is anticipated to extend cash runway into the fourth quarter of 2025 to support the continued |
Taysha Gene Therapies, Inc. (TSHA) Just Flashed Golden Cross Signal: Do You Buy?Is it a good or bad thing when a stock experiences a golden cross technical event? |
3 Small-Cap Stocks to Sell in September Before They Crash & BurnA lot of speculative companies enjoyed strong rallies in the summer. |
Taysha Gene Therapies Announces Fast Track Designation Granted by U.S. FDA for TSHA-102 in Rett SyndromeFast Track Designation (FTD) is designed to accelerate the development and expedite the review of therapies with potential to address unmet medical needs for a serious or life-threatening condition TSHA-102 has also received Orphan Drug and Rare Pediatric Disease designations from the United States (U.S.) Food and Drug Administration (FDA) and has been granted Orphan Drug designation from the European Commission DALLAS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on TuesdayPre-market stock movers are a hot topic with investors this morning and we're checking out the biggest ones worth watching on Tuesday! |
TSHA Price Returns
| 1-mo | 44.72% |
| 3-mo | 336.36% |
| 6-mo | 323.53% |
| 1-year | 26.87% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 27.43% |
| 2022 | -80.60% |
| 2021 | -56.10% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...